<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597139</url>
  </required_header>
  <id_info>
    <org_study_id>AUR-VOS-2017-01</org_study_id>
    <nct_id>NCT03597139</nct_id>
  </id_info>
  <brief_title>Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease</brief_title>
  <official_title>An Investigator-Masked, Randomized, Parallel-Group Study of the Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild&#xD;
      to moderate Dry Eye Disease (DED).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to&#xD;
      evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day&#xD;
      treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be&#xD;
      randomized to either VOS or Restasis® at approximately 7 centers located in the US&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Actual">December 13, 2018</completion_date>
  <primary_completion_date type="Actual">November 9, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be randomized to either VOS or Restasis® at approximately 7 centers located in the US.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1</measure>
    <time_frame>1-minute Post Dose 1 installation (Day 1)</time_frame>
    <description>Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to &quot;no discomfort&quot; and 100 corresponds to &quot;maximal discomfort&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no discomfort&quot; and 100 corresponds to &quot;maximal discomfort&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no burning/stinging&quot; and 100 corresponds to &quot;worst burning/stinging&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no foreign body sensation&quot; and 100 corresponds to &quot;worst foreign body sensation&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Photophobia Post Dose Instillation on Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no photophobia&quot; and 100 corresponds to &quot;worst photophobia&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eye Pain Post Dose Instillation on Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no eye pain&quot; and 100 corresponds to &quot;worst eye pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eye Dryness Post Dose Instillation on Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no eye dryness&quot; and 100 corresponds to &quot;worst eye dryness&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Itching Post Dose Instillation on Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no itching&quot; and 100 corresponds to &quot;worst itching&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores</measure>
    <time_frame>Day 28</time_frame>
    <description>The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)</measure>
    <time_frame>Day 28</time_frame>
    <description>The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = &quot;rarely&quot; and 100mm = &quot;all the time&quot;. For Severity of Symptoms 0mm = &quot;very mild&quot; and 100mm = &quot;very severe&quot;. Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an &quot;X&quot; on the relevant horizontal line. The length of the line between the &quot;rarely&quot; or &quot;very mild&quot; starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Unanesthetized Schirmer Test Score</measure>
    <time_frame>28 days</time_frame>
    <description>The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is &lt;5mm of wetting on the test strip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fluorescein Corneal Staining (FCS) Score</measure>
    <time_frame>28 days</time_frame>
    <description>The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Voclosporin ophthalmic solution (VOS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voclosporin Ophthalmic Solution</intervention_name>
    <description>Investigational Drug</description>
    <arm_group_label>Voclosporin ophthalmic solution (VOS)</arm_group_label>
    <other_name>0.2% VOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis®</intervention_name>
    <description>Comparator</description>
    <arm_group_label>Comparator</arm_group_label>
    <other_name>RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a best corrected visual acuity (BCVA) in both eyes of +0.7 logarithm of the&#xD;
             Minimum Angle of Resolution (logMAR) or better as assessed by Early Treatment of&#xD;
             Diabetic Retinopathy Study (ETDRS) chart.&#xD;
&#xD;
          2. Have a documented history of DED in both eyes supported by a previous clinical&#xD;
             diagnosis.&#xD;
&#xD;
          3. Have ongoing DED, as defined by at least one eye (if one eye, the same eye) meeting&#xD;
             all the following criteria:&#xD;
&#xD;
               -  A symptom severity score of ≥30 for Eye Dryness on a Visual Analog Scale (VAS)&#xD;
                  (0-100)&#xD;
&#xD;
               -  An unanesthetized Schirmer Tear Test (STT) score of ≥1 mm and ≤10 mm per 5&#xD;
                  minutes (Note: STT Score obtained at Visit 1)&#xD;
&#xD;
               -  Evidence of ocular surface staining (total fluorescein staining score of at least&#xD;
                  3 [0-15 scale]).&#xD;
&#xD;
          4. Have normal lid anatomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have any known hypersensitivity or contraindication to study treatments (including&#xD;
             excipients), topical anesthetics or vital dyes.&#xD;
&#xD;
          2. Be unable to demonstrate correct instillation of over-the-counter (OTC) ocular&#xD;
             lubricant.&#xD;
&#xD;
          3. Report discomfort in both eyes from instillation of OTC ocular lubricant during Visit&#xD;
             2 (based on score of ≥30 on the Drop Discomfort VAS).&#xD;
&#xD;
          4. Have used Restasis® (cyclosporine ophthalmic emulsion) within 30 days prior to Visit&#xD;
             1.&#xD;
&#xD;
          5. Have used Restasis® for more than 1 month (if prior use is reported).&#xD;
&#xD;
          6. Have used Xiidra® (lifitegrast ophthalmic solution) within 14 days prior to Visit 1.&#xD;
&#xD;
          7. Have had corneal graft surgery in either eye within 1 year.&#xD;
&#xD;
          8. Have recent or current evidence of ocular infection or inflammation in either eye.&#xD;
&#xD;
          9. Have current evidence of clinically significant blepharitis (defined as requiring lid&#xD;
             hygiene therapy), conjunctivitis, or a history of herpes simplex or zoster keratitis&#xD;
             in either eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <results_first_submitted>March 10, 2021</results_first_submitted>
  <results_first_submitted_qc>July 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <disposition_first_submitted>January 22, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 5, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 8, 2021</disposition_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Calcineurin Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: aur-vos-2017-01-protocol-v1_Redacted</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03597139/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: aur-vos-2017-01-protocol-v2_Redacted</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03597139/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: aur-vos-2017-01-protocol-v3_Redacted</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03597139/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03597139/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period from August 2018 - December 2018</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Voclosporin Ophthalmic Solution (VOS)</title>
          <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
        </group>
        <group group_id="P2">
          <title>Comparator</title>
          <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Voclosporin Ophthalmic Solution (VOS)</title>
          <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
        </group>
        <group group_id="B2">
          <title>Comparator</title>
          <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="14.51"/>
                    <measurement group_id="B2" value="60.2" spread="15.08"/>
                    <measurement group_id="B3" value="58.9" spread="14.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Dry Eye Disease</title>
          <description>Number of years subject has had Dry Eye Disease</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.85" lower_limit="1.62" upper_limit="6.13"/>
                    <measurement group_id="B2" value="2.67" lower_limit="1.25" upper_limit="6.27"/>
                    <measurement group_id="B3" value="2.85" lower_limit="1.45" upper_limit="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1</title>
        <description>Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to &quot;no discomfort&quot; and 100 corresponds to &quot;maximal discomfort&quot;.</description>
        <time_frame>1-minute Post Dose 1 installation (Day 1)</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1</title>
          <description>Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to &quot;no discomfort&quot; and 100 corresponds to &quot;maximal discomfort&quot;.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="17.95"/>
                    <measurement group_id="O2" value="3.5" spread="13.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1491</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28</title>
        <description>Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no discomfort&quot; and 100 corresponds to &quot;maximal discomfort&quot;.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28</title>
          <description>Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no discomfort&quot; and 100 corresponds to &quot;maximal discomfort&quot;.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="20.64"/>
                    <measurement group_id="O2" value="6.1" spread="17.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1187</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28</title>
        <description>Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no burning/stinging&quot; and 100 corresponds to &quot;worst burning/stinging&quot;.</description>
        <time_frame>Day 28</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28</title>
          <description>Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no burning/stinging&quot; and 100 corresponds to &quot;worst burning/stinging&quot;.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="33.22"/>
                    <measurement group_id="O2" value="-20.1" spread="25.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2128</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>16.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28</title>
        <description>Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no foreign body sensation&quot; and 100 corresponds to &quot;worst foreign body sensation&quot;.</description>
        <time_frame>28 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28</title>
          <description>Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no foreign body sensation&quot; and 100 corresponds to &quot;worst foreign body sensation&quot;.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.7" spread="35.8"/>
                    <measurement group_id="O2" value="-20.7" spread="32.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8408</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.8</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Photophobia Post Dose Instillation on Day 28</title>
        <description>Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no photophobia&quot; and 100 corresponds to &quot;worst photophobia&quot;.</description>
        <time_frame>28 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Photophobia Post Dose Instillation on Day 28</title>
          <description>Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no photophobia&quot; and 100 corresponds to &quot;worst photophobia&quot;.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="26.35"/>
                    <measurement group_id="O2" value="-26.2" spread="25.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5356</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eye Pain Post Dose Instillation on Day 28</title>
        <description>Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no eye pain&quot; and 100 corresponds to &quot;worst eye pain&quot;.</description>
        <time_frame>28 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eye Pain Post Dose Instillation on Day 28</title>
          <description>Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no eye pain&quot; and 100 corresponds to &quot;worst eye pain&quot;.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" spread="31.39"/>
                    <measurement group_id="O2" value="-19.9" spread="28.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1787</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eye Dryness Post Dose Instillation on Day 28</title>
        <description>Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no eye dryness&quot; and 100 corresponds to &quot;worst eye dryness&quot;.</description>
        <time_frame>28 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eye Dryness Post Dose Instillation on Day 28</title>
          <description>Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no eye dryness&quot; and 100 corresponds to &quot;worst eye dryness&quot;.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.0" spread="27.59"/>
                    <measurement group_id="O2" value="-34.6" spread="27.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7666</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>9.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Itching Post Dose Instillation on Day 28</title>
        <description>Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no itching&quot; and 100 corresponds to &quot;worst itching&quot;.</description>
        <time_frame>28 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Itching Post Dose Instillation on Day 28</title>
          <description>Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to &quot;no itching&quot; and 100 corresponds to &quot;worst itching&quot;.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.9" spread="27.41"/>
                    <measurement group_id="O2" value="-28.1" spread="30.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8082</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores</title>
        <description>The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).</description>
        <time_frame>Day 28</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores</title>
          <description>The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-130.9" spread="144.95"/>
                    <measurement group_id="O2" value="-149.6" spread="126.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6362</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37</ci_lower_limit>
            <ci_upper_limit>60.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)</title>
        <description>The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = &quot;rarely&quot; and 100mm = &quot;all the time&quot;. For Severity of Symptoms 0mm = &quot;very mild&quot; and 100mm = &quot;very severe&quot;. Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an &quot;X&quot; on the relevant horizontal line. The length of the line between the &quot;rarely&quot; or &quot;very mild&quot; starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.</description>
        <time_frame>Day 28</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)</title>
          <description>The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = &quot;rarely&quot; and 100mm = &quot;all the time&quot;. For Severity of Symptoms 0mm = &quot;very mild&quot; and 100mm = &quot;very severe&quot;. Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an &quot;X&quot; on the relevant horizontal line. The length of the line between the &quot;rarely&quot; or &quot;very mild&quot; starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.0" spread="29.37"/>
                    <measurement group_id="O2" value="-37.9" spread="27.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.9" spread="34.06"/>
                    <measurement group_id="O2" value="-36.1" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Frequency</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0961</p_value>
            <p_value_desc>Frequency</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>20.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Severity</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1722</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>18.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Unanesthetized Schirmer Test Score</title>
        <description>The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is &lt;5mm of wetting on the test strip.</description>
        <time_frame>28 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unanesthetized Schirmer Test Score</title>
          <description>The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is &lt;5mm of wetting on the test strip.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="10.52"/>
                    <measurement group_id="O2" value="3.0" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="10.64"/>
                    <measurement group_id="O2" value="3.3" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Left Eye</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0051</p_value>
            <p_value_desc>Left Eye</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Right Eye</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0104</p_value>
            <p_value_desc>Right Eye</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fluorescein Corneal Staining (FCS) Score</title>
        <description>The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.</description>
        <time_frame>28 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Ophthalmic Solution (VOS)</title>
            <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fluorescein Corneal Staining (FCS) Score</title>
          <description>The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.</description>
          <population>Intent to Treat</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.90"/>
                    <measurement group_id="O2" value="-0.2" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="3.15"/>
                    <measurement group_id="O2" value="-0.7" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Left Eye</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Left Eye</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
            <estimate_desc>Add in RE LE info</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Right Eye</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>Right Eye</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days +/- 3 days (follow-up period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Voclosporin Ophthalmic Solution (VOS)</title>
          <description>0.2% VOS, Twice Daily (BID), both eyes for 28 days&#xD;
Voclosporin Ophthalmic Solution: Investigational Drug</description>
        </group>
        <group group_id="E2">
          <title>Comparator</title>
          <description>0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days&#xD;
Restasis®: Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA V21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Discomfort</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Palmen</name_or_title>
      <organization>Aurinia Pharmaceuticals</organization>
      <phone>1 (250) 744-2487</phone>
      <email>clinicaltrials@auriniapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

